GHS, ITOR and Selah to transform cancer care with genetic testing

April 28, 2013

Thanks to an innovative Greenville Health System partnership with Selah Genomics, a new gene-based diagnostic test is paving the way for more precise and potentially far more effective cancer treatment at GHS.

This is the first time that this type of advanced genetic test has been developed, validated and employed in a clinical setting in South Carolina to empower oncologists to tailor specific treatment plans based on the particular molecular profile of each patient’s cancer.

Selah’s PrecisionPathTM test, which was developed with clinical guidance from GHS oncologists, addresses the game-changing redefinition of the classification of cancer.

Read the full article from The Wall Street Journal.